CN1280007A - Jew's-ear blood fat regulating capsule - Google Patents
Jew's-ear blood fat regulating capsule Download PDFInfo
- Publication number
- CN1280007A CN1280007A CN 00121044 CN00121044A CN1280007A CN 1280007 A CN1280007 A CN 1280007A CN 00121044 CN00121044 CN 00121044 CN 00121044 A CN00121044 A CN 00121044A CN 1280007 A CN1280007 A CN 1280007A
- Authority
- CN
- China
- Prior art keywords
- auricularia
- capsule
- extract
- water extract
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention relates to a kink of capsule of water-extracted Jew's ear extract and a preparation process of water-extracted Jew's ear extract with blood fat regulating function. The said capsule has high curative effect of regulating blood fat.
Description
The present invention relates to a kind of Auricularia water extract capsule, and have Auricularia water extract of blood lipid regulation effect and preparation method thereof with blood lipid regulation effect.
Hyperlipemia is the important pathogenic factors of atherosclerosis, and preventing and treating hyperlipemia is the important step of preventing and treating senile disease such as coronary heart disease, apoplexy.Along with increasing of sickness rate, hyperlipemia healthhazard, paid more and more attention.In recent years, people have carried out number of research projects, mostly be Western medicine but be applied to clinical lipid lowerers at present, but they have obvious toxic and side effects, and therefore, reality needs exploitation to truly have the Chinese medicine lipid lowering agent of curative effect.
Hyperlipemia is meant a kind of pathological state that the blood fat composition increases unusually.According to theory of Chinese medical science, belong to expectorant, the stasis of blood category of the traditional Chinese medical science.The generation of hyperlipemia, how relevant with the thanks to empty imbalance of spleen, liver, kidney, or because of the natural endowment deficiency, or improper because of taking good care of the day after tomorrow, rich and fatty diet, or thanks to empty because of older visceral-qi, make dysfunction of the spleen in transportation, the liver failing to maintain the normal flow of QI, kidney essense loss, cause dysfunction of the spleen in transportation and transformation, stop in the turbid damp, it is turbid change to give birth to expectorant, slime flux blood vessels and causing a disease.Event is clinical sees that deficiency-weakness of spleen-QI is arranged more, the syndrome of deficiency of both the liver and kidney, and to the treatment of hyperlipemia, the at present domestic method of treatment such as invigorating the spleen and benefiting QI, nourishing the liver and kidney, dampness removing eliminate the phlegm, blood circulation promoting and blood stasis dispelling that adopt more.
Basidiomycetes Auriculariaceae plant Auricularia Auricularia auricul (L.ex Hook) Underw, effect with good edible and disease preventing and treating, loaded China " Chinese medicine voluminous dictionary ", and record in version ministry standard in 1992, indicating this medical instrument has effects such as QI invigorating is kept fit, invigorated blood circulation, hemostasis, relaxing muscles and tendons and activating QI and blood in the collateral.The Auricularia nature and flavor are sweet flat, go into spleen, liver, kidney channel (" book on Chinese herbal medicine is new again "), experiment and clinical research confirmation, and this medicine treatment deficiency of spleen-QI or double expectorant hyperlipidemia patient turbid, blood stasis have good pharmacological action and clinical efficacy.
Existing a lot of in the prior art for the report of Auricularia curative effect, treat the form that also adopts the Auricularia water preparation mostly and use Auricularia.But because Auricularia water extract hydrophilic is strong, viscosity is bigger, therefore, generally is mixed with rarer water preparation, and the transportation kimonos uses very inconvenient and easy moldy metamorphism.The more important thing is, utilize the therapeutic effect of water preparation not very good.
The present inventor is through research for many years, finally found to have assimilation effect in the better body, and the capsule that contains the Auricularia water extract with blood lipid regulation effect evident in efficacy, and it is strong at the easy moisture absorption of Auricularia, water extract hydrophilic, the great characteristics of viscosity have been invented the preparation method of the better Auricularia water extract of a kind of extraction effect and the Auricularia water extract with blood lipid regulation effect for preparing by described method.
Therefore, the invention provides a kind of capsule with Auricularia water extract of blood lipid regulation effect, this capsule contains Auricularia water extract and the pharmaceutically acceptable capsule carrier or the excipient for the treatment of effective dose.
Wherein said Auricularia water extract makes according to following method, gets Auricularia and adds 30-80 times of water (w/w), extracts down at 70-98 ℃, filter, repeat to extract 1-4 time merging filtrate, in 60-80 ℃ of following concentrating under reduced pressure, being concentrated into 70 ℃ of following proportions is 1.01-1.20g/cm
3, concentrated solution is cooled to room temperature, stirs to add doubly (w/w) ethanol of 2-5 down, leaves standstill, filter, and the precipitate washing with alcohol, vacuum drying obtains the Auricularia water extract.
In the preferred embodiment of the invention, the consumption of water is 50 times of Auricularia preferably, preferably extract down at 80-90 ℃, extraction time is preferably 2 hours, the preferred extraction twice, the filtrate that merges is concentrating under reduced pressure under the 60-80KPa at 70 ℃, vacuum preferably, the gained concentrated solution 70 ℃ of following specific gravity control at 1.10g/cm
3, use medicinal ethanol usually, particularly 95% ethanol makes the concentrated solution precipitation, and the ethanol use amount is preferably 3 times concentrated solution (w/w), and precipitate is preferably used 95% washing with alcohol, and gained dry product water content preferably is lower than 5%.
Pharmaceutically acceptable capsule carrier or diluent described in the above-mentioned capsule are the capsule carrier or the diluent of pharmaceutical field routine, for example, sugar is as glucose, fructose, lactose and sucrose etc., starch such as corn starch, horse bell administration starch etc., cellulose such as microcrystalline Cellulose, methylcellulose, the low hydroxypropyl cellulose (L-HPC) that replaces etc.
Bonding is agglomerating because Auricularia water extract dry powder very easily absorbs water, and is unfavorable for preparation processing.Therefore, the inventor specifically selects described pharmaceutically acceptable carrier or excipient according to the characteristic of Auricularia water extract, for example in that the Auricularia water extract is pulverized, adds microcrystalline Cellulose in the granulation process, to play dilution and to help disintegration; Add hexadecanol to reduce surface hydrophilicity, make granule non-caked agglomerating.
Thus, capsule with Auricularia water extract of blood lipid regulation effect of the present invention, this capsule contains Auricularia water extract, microcrystalline Cellulose, L-HPC, hexadecanol and 95% ethanol, and wherein the Auricularia water extract accounts for 70-90%, and water extract Auricularia total sugar is with glucose (C
6H
12O
6) meter is not less than 100mg.Preferably, the capsule with Auricularia water extract of blood lipid regulation effect of the present invention, wherein said Auricularia water extract makes according to the said extracted method, and gained water extract Auricularia total sugar is with glucose (C
6H
12O
6) meter is not less than 100mg.
The Auricularia water extract that makes according to the method described above has following feature: 1. character: brown, and feeble QI, it is dense to distinguish the flavor of, and easily the moisture absorption is dissolved in hot water, is slightly soluble in cold water and rare alcohol, is insoluble to high concentration ethanol; 2. moisture determination: method is seen " pharmacopeia " 90 editions appendix 30, water content≤5%; 3. assay: total sugar content records content 〉=54% ± 5.4% by the phenolsulfuric acid method.
Auricularia water extract capsule of the present invention has invigorating the spleen and benefiting QI, nourishing the liver and kidney, blood circulation promoting and blood stasis dispelling, the effect of relaxing muscles and tendons and activating QI and blood in the collateral.Can be used for spiritlessness and weakness, deficiency of QI with disinclination to talk, dizzy cardiopalmus, the vexed and deficiency-weakness of spleen-QI of breast gastral cavity painful abdominal mass, the hyperlipemia of the turbid blood stasis type of expectorant.Take capsule preferred for preparation of the present invention and become the unit capsule, the dosage of its per unit capsule, with contained Auricularia total sugar wherein with glucose (C
6H
12O
6) meter be not less than 100mg, be preferably 100mg-1000mg.Preferably, Jew ' s-ear capsule agent of the present invention be mixed with each capsule contain sugar with glucose meter 100mg.The amount of taking described Jew ' s-ear capsule agent every day can change according to multiple different factors, and described factor comprises the purpose that treats and/or prevents, patient's age, body weight and health etc.Concrete dosage can be determined according to conventional method as the case may be by the doctor.Preferably, 300mg-1000mg is used in Jew ' s-ear capsule agent of the present invention every day.
The present invention will further illustrate by the following example, and these embodiment only are used for illustration purpose at this, and protection domain of the present invention is not played any qualification effect.
Embodiment 1
The preparation of Auricularia water extract
Standard compliant Auricularia medical material 100g (sugar content is not less than 40g) is cleaned, remove impurity, the extraction pot that places band to stir adds 50 times of water (w/w), extracted 2 hours in 80-90 ℃, filter, filtering residue repeats to extract once, filters, merge secondary filtrate, in 70 ℃ of concentrating under reduced pressure, vacuum is 60-80KPa, and the terminal point concentrated solution is 1.1g/cm at 70 ℃ of following proportions
3, concentrated solution is cooled to room temperature, weighs, and in stirring the medicinal alcohol that adds 3 times of (w/w) 95% down, the washing secondary filters, and precipitate is at 65 ℃ of following vacuum dryings, and the dry product water content is lower than 5%, extract yield＞15%.
The Auricularia crude drug should meet ministry standard 92 editions.Polyoses content following (n=3) in the Auricularia of several different places of production
| The place of production | Sichuan | Yunnan | Jiangxi | Northeast | Hubei |
| Polyoses content % | 45．3 | 46．5 | 44．2 | 47．3 | 47．2 |
Embodiment 2-5
The preparation of Auricularia water extract
According to embodiment 1 described method, just select following factor A. extract temperature (℃) A1=65 A2=85 A3=100B. extracts the water yield (times w/w) B1=30 B2=50 B3=80C. extraction time C1=2 C2=3
Extract according to different factors, the result is as follows:
| Embodiment number | ????A | ????B | ????C | Yield (%) |
| ????2 | ????1 | ????2 | ????2 | ????13．0 |
| ????3 | ????2 | ????2 | ????2 | ????15．4 |
| ????4 | ????2 | ????3 | ????1 | ????15．4 |
| ????5 | ????3 | ????2 | ????2 | ????15．3 |
Embodiment 6
The preparation of capsule
Prepare capsule according to following component: Auricularia water extract 200g microcrystalline Cellulose 20gL-HPC 12.5g hexadecanol 17.25g95% ethanol is an amount of
The Auricularia water extract is pulverized, crossed 100 mesh sieves, get 200g, with itself and low-substituted hydroxypropyl cellulose 12.5g, microcrystalline Cellulose 20g mix homogeneously; Hexadecanol 17.25g stirred add down in warm 95% ethanol, about 150ml, it is dissolved fully after, with the said two devices mixing granulation, be dried to water content≤5% granulate afterwards under 60 ℃, filled capsules, every contains Auricularia extract 200mg.
Differentiate: (1) described capsule content contains Auricularia polycose, does not contain free monosaccharide, so sample for reference carries out tlc analysis under situation about not being hydrolyzed, the result loses has corresponding speckle to occur, and proves not have free monosaccharide in the content.And the capsule content carries out tlc analysis through hydrolysis, shows the speckle of D-mannose, D-xylose, glucuronic acid and glucose.
(2) aqueous solution of capsule content adds iodine test solution and does not show blueness, proves not starch-containing class polysaccharide.
(3) aqueous solution of capsule content adds ninhydrin reagent, and heating shows bluish violet, proves that content contains peptidoglycan.
Embodiment 7
Auricularia water extract capsule is to the regulating action of blood fat
Utilize embodiment 6 described Jew ' s-ear blood fat regulating capsules, obtain following result of the test:
1. Jew ' s-ear blood fat regulating capsule of the present invention was to experimental hyperlipidemia rabbit treatment 15 days, three dosage all can make TC, TG, LDL-C, VLDL-C, TC/HDL-C obviously reduce, and the HDL-C that can raise, the effect of middle high dose similar to fenofibrate (seeing Table 1).
2. Jew ' s-ear blood fat regulating capsule of the present invention obviously reduces TC (serum total cholesterol), TG (triglyceride), LDL-C (low-density lipoprotein cholesterol), VLDL-C (C-VLDL), TC/HDL-C (HDL-C) value (seeing Table 2) to experimental hyperlipidemia rabbit prevention administration after the 10th day and the 25th day.
3. Jew ' s-ear blood fat regulating capsule of the present invention was to experimental hyperlipidemia rat prevention administration the 10th day, three remarkable cholesterol reducing of dosage (TC) content, middle and high dosage group can obviously reduce the value of TG, LDL-C, CLDL-C, TC/HDL-C, its effect similar to fenofibrate (seeing Table 3).Table 1. Jew ' s-ear blood fat regulating capsule is to the therapeutical effect of rabbit hyperlipemia
Annotate: I: be the normal value of giving high lipid food, II: for feeding high lipid food blood fat value after 10 days, III: be administration blood fat value after 15 days
| The group testing index | High fat matched group | The fenofibrate group | Jew ' s-ear blood fat regulating-I | Jew ' s-ear blood fat regulating-II | Jew ' s-ear blood fat regulating-III | |
| N dosage mg/kg | ????7 | ????6 ????14 | ????6 ????37 | ????6 ????74 | ????6 ????110 | |
| TC value mg/DL | ?Ⅰ ?Ⅱ ?Ⅲ | ?72.31±19.66 ?158.65±20.76 ????????????* ?148.76±12.29 | ?76.98±20.52 ?106.53±22.27 ???????????*** ?100.73±14.40 ????????△△△ | 80.95±22.23 64.28±19.85 ????**△△△ 30.44±11.34 ????▲▲▲ | ?80.32±14.85 ?165.79±14.51 ?????***△△△ ?111.96±9.09 ????????????▲ | ?79.76±14.96 ?166.67±21.44 ?????***△△△ ?104.35±10.65 ???????????▲ |
| TG value mg/DL | ?Ⅰ ?Ⅱ ?Ⅲ | ?102.86±8.83 ?162.20±22.65 ????????????* ?170.00±18.66 | ?100.21±18.16 ?148.29±9.92 ????????????** ?122.78±12.19 ????????△△△ | 12.71±9.16 47.44±8.39 ????**△△△ 140.56±11.04 ?????▲▲▲ | ?105.73±14.44 ?147.01±12.84 ??????**△△△ ?130.56±14.82 ????????????▲ | ?108.96±9.24 ?152.14±5.53 ????**△△△ ?126.11±16.39 ???????????▲ |
| HDL-C mg/DL | ?Ⅰ ?Ⅱ ?Ⅲ | ?58.39±9.85 ?66.98±10.39 ???????????* ?76.84±5.85 | ?62.98±5.50 ?72.68±9.08 ?????????*** ?90.91±4.29 ??????△△△ | 64.21±5.12 74.86±12.85 ??????**△ 77.53±6.67 ????▲▲▲ | ?63.51±10.63 ?74.32±15.44 ??????***△△ ?84.60±5.94 ???????????▲ | ?65.97±5.59 ?67.76±8.40 ??***△△△ ?88.64±3.29 ?????????▲ |
| LDL-C mg/DL | ?Ⅰ ?Ⅱ ?Ⅲ | ?46.98±9.71 ?73.91±7.24 ???????????* ?73.73±4.89 | ????44.36±3.22 ????72.15±12.23 ?????????????** ????54.60±3.95 ?????????△△△ | 43.48±6.76 ?75.43±14.19 ????**△△△ 68.63±8.95 ????▲▲▲ | ?41.58±11.63 ?77.69±9.43 ????**△△△ ?64.76±4.39 ??????▲▲▲ | ?41.66±6.45 ?77.94±6.05 ??***△△△ ?56.24±6.02 ????????▲ |
| VLDL-C mg/DL | ?Ⅰ ?Ⅱ ?Ⅲ | ?20.57±1.77 ?32.44±4.53 ???????????* ?34.00±3.73 | ????20.04±3.63 ????29.66±1.98 ?????????????** ????24.56±2.44 ?????????△△△ | 22.54±1.83 29.49±1.68 ???**△△△ 28.11±2.21 ??????▲▲ | ?21.15±2.89 ?29.42±2.57 ????**△△△ ?26.11±2.96 ??????????▲ | ?21.79±1.85 ?30.43±1.11 ?????**△△△ ?25.22±3.28 ?????????▲ |
| TC/HDL-C | ?Ⅰ ?Ⅱ ?Ⅲ | ?1.26±0.39 ?2.08±0.53 ??????????* ?1.84±0.19 | ????1.24±0.40 ????2.25±0.51 ???????????*** ????1.13±0.13 ????????△△△ | 1.27±0.33 ?2.11±0.60 ??????**△ 1.69±0.12 ????▲▲▲ | ?1.28±0.22 ?2.28±0.32 ???***△△△ ?1.34±0.20 ??????????▲ | ?1.23±0.29 ?2.47±0.26 ??***△△△ ?1.18±0.15 ?????????▲ |
* P＞0.05, * * P＜0.05, own control before and after * * * P＜0.01 administration.
△ P＞0.05, △ △ P＜0.05, compare with high fat matched group △ △ △ P＜0.01
▲ P＞0.05, ▲ ▲ P＜0.05, ▲ ▲ ▲ compare with the fenofibrate group P＜0.01.Table 2. Jew ' s-ear blood fat regulating capsule is to the preventive effect of rabbit hyperlipemia
Annotate: I: be normal value before the administration.II: be administration blood fat value after 10 days, III: be administration blood fat value after 25 days.
| The group testing index | High fat matched group | The fenofibrate group | Jew ' s-ear blood fat regulating-I | Jew ' s-ear blood fat regulating-II | Jew ' s-ear blood fat regulating-III | |
| N dosage mg/kg | ????7 | ????6 ????14 | ????6 ????37 | ????6 ????74 | ????6 ????110 | |
| TC value mg/DL | ?Ⅰ ?Ⅱ ?Ⅲ | ?72.31±19.66 ?135.49±26.44 ?14.68±10.41 | 70.51±6.79 ????????*** 83.23±13.73 ????????*** 74.83±3.54 | 67.62±7.57 ??????????** 110.90±8.71 ??????△△△ ?????????*** 102.90±6.40 ???????△△△ | 73.69±8.66 ??????????** 100.00±9.42 ????????△△ ?????????*** 92.75±9.88 ???????△△△ | 73.84±14.78 ????????*** 8.85±14.50 ?????????△ ????????*** 78.26±5.14 ??????????△ |
| TC value mg/DL | ?Ⅰ ?Ⅱ ?Ⅲ | ?102.86±8.83 ?168.25±25.20 ?170.00±18.66 | 107.16±8.42 ?????????*** 95.83±19.39 ?????????*** 91.67±13.79 | 98.66±12.35 ???????????** 138.89±20.79 ???????△△△ ??????????*** 115.00±12.61 ?????????△△ | 100.64±12.80 ??????????*** 115.26±15.90 ???????????△ ??????????*** 100.00±7.12 ??????????△ | 104.30±8.56 ?????????*** 99.26±22.95 ??????????△ ?????????*** 96.67±7.89 ?????????△ |
| HDL-C mg/DL | ?Ⅰ ?Ⅱ ?Ⅲ | ?58.39±9.85 ?66.98±10.39 ?76.84±5.85 | 61.05±9.76 ??????????* 77.30±13.84 ??????????* 83.84±5.64 | 56.24±6.43 ???????????* 66.39±7.31 ??????????△ ???????????* 75.26±8.44 ??????????△ | 56.63±6.76 ??????????* 69.33±12.63 ??????????△ ??????????* 83.34±5.67 ??????????△ | 62.95±4.85 ?????????* 74.61±12.99 ?????????△ ?????????* 85.61±8.45 ?????????△ |
| LDL-C mg/DL | ?Ⅰ ?Ⅱ ?Ⅲ | ?46.98±9.71 ?73.91±7.24 ?73.73±4.89 | 47.17±9.61 ????????*** 51.53±9.65 ????????*** 47.57±7.62 | 46.18±9.33 ?????????** 61.19±8.85 ?????????△ ????????*** 57.61±10.29 ?????????△ | 48.11±10.68 ?????????*** 59.91±7.85 ??????????△ ?????????*** 52.88±5.06 ??????????△ | 42.76±10.09 ????????*** 48.76±13.08 ?????????△ ????????*** 43.88±5.73 ?????????△ |
| VLDL-C mg/DL | ?Ⅰ ?Ⅱ ?Ⅲ | ?20.57±1.77 ?33.65±5.04 ?34.00±37.3 | 21.43±1.68 ????????*** 19.17±3.88 ????????*** 18.33±2.76 | 19.73±2.47 ?????????** 27.78±4.16 ?????△△△ ????????*** 23.00±2.52 ???????△△ | 20.13±2.56 ?????????** 23.05±3.18 ?????????△ ????????*** 20.11±1.42 ?????????△ | 20.86±1.71 ????????*** 19.85±4.59 ?????????△ ????????*** 19.33±1.58 ?????????△ |
| TC/HDL-C mg/DL | ?Ⅰ ?Ⅱ ?Ⅲ | ?1.26±0.39 ?2.08±0.53 ?1.84±0.19 | 1.20±0.18 ???????*** 1.11±0.34 ???????*** 0.89±0.08 | ?1.25±0.20 ?????????* ?1.68±0.18 ????△△△ ???????*** 1.05±0.10 ??????△△ | 1.30±0.13 ????????** 1.46±0.25 ????????△ ???????*** 1.12±0.17 ??????△△ | 1.23±0.31 ???????*** 1.22±0.26 ????????△ ???????*** 0.92±0.11 ????????△ |
* P＞0.05, * * P＜0.05, * * * P＜0.01 and the comparison of high fat matched group.
△ P＞0.05, △ △ P＜0.05, compare with the fenofibrate group △ △ △ P＜0.01.Table 3. Jew ' s-ear blood fat regulating capsule is to the preventive effect of serum lipids in rats
Annotate: carry out the t assay.
| Testing index | The normal saline group | High fat matched group | The fenofibrate group | Jew ' s-ear blood fat regulating-I | Jew ' s-ear blood fat regulating-II | Jew ' s-ear blood fat regulating-III |
| Heavy (g) TC (mg/DL) TC (mg/DL) HDL-C (mg/DL) LDL-C (mg/DL) VDL-C (mg/DL) TC/HDL-C after heavy (g) administration before dosage mg/kg * d administration | ?200.22±10.29 ?242.22±7.56 ?84.44±22.23 ?99.88±22.11 ?103.06±18.63 ?32.24±9.60 ?19.98±4.42 ?0.834±0.267 | ?198.89±12.12 ?240.56±9.06 ?278.73±51.41 ?145.06±30.95 ?115.94±14.99 ?101.05±34.94 ?29.01±6.35 ?2.45±0.60 | ?27×10 ?204.89±11.25 ?240.78±5.72 ??????????*** ?154.60±25.49 ??????????*** 103.54±24.80 ???????????* 128.50±27.80 ?????????*** 60.74±20.95 ????????*** 20.71±4.96 ???????*** 1.23±0.25 | ????35×10 ?200.11±10.53 ?237.00±10.27 ??????????*** ?209.91±36.82 ????????△△△ ????????????* 135.09±33.23 ?????????△△ ????????????* 103.22±21.52 ?????????△△ ???????????* 78.17±21.94 ?????????△△ ???????????* 27.02±6.65 ?????????△△ ???????????* 2.07±0.38 ??????△△△ | 70×10 201.22±12.60 237.56±9.08 ??????????*** 191.11±25.85 ???????△△△ ???????????** 115.12±19.31 ???????????△ ???????????* 105.15±15.04 ?????????△△ ??????????** 68.05±14.58 ??????????△ ??????????** 23.02±3.86 ??????????△ ??????????** 1.84±0.32 ????△△△ | 105×10 201.44±10.90 240.78±7.71 ??????????*** 153.02±23.35 ???????????△ ??????????*** 104.7±18.29 ???????????△ ????????????* 112.56±18.58 ???????????△ ???????????** 65.22±12.51 ???????????△ ??????????*** 20.95±3.66 ??????????△ ??????????*** 1.40±0.30 ??????????△ |
* P＞0.05, * * P＜0.05, * * * P＜0.01 be and high fat matched group relatively.
△ P＞0.05, △ △ P＜0.05, △ △ △ P＞0.01 are to compare with the fenofibrate group.
Claims (9)
1. capsule with Auricularia water extract of blood lipid regulation effect, this capsule contains Auricularia water extract and the pharmaceutically acceptable capsule carrier or the excipient for the treatment of effective dose.
2. according to the described Auricularia water extract of claim 1 capsule, this capsule contains Auricularia water extract, microcrystalline Cellulose, L-HPC, hexadecanol and 95% ethanol, and wherein the Auricularia water extract accounts for 70-90%, and water extract Auricularia total sugar is with glucose (C
6H
12O
6) meter is not less than 100mg.
3. according to the described Auricularia water extract of claim 1 capsule, this capsule contains following component and is mixed with the capsule that every seed lac wafer contains 200mg Auricularia water extract:
Auricularia water extract 200g
Microcrystalline Cellulose 20g
L-HPC?????????12．5g
Hexadecanol 17.25g
95% ethanol is an amount of
4. the described capsule of arbitrary claim among the claim 1-3, wherein said Auricularia water extract makes as follows: get Auricularia and add 30-80 times of water (w/w), extract down at 70-98 ℃, filter, repeat to extract for several times merging filtrate, in 60-80 ℃ of following concentrating under reduced pressure, concentrated solution is cooled to room temperature, stirs to add doubly (w/w) ethanol of 2-5 down, leaves standstill, filter, the precipitate washing with alcohol, vacuum drying obtains the Auricularia water extract.
5. according to the described capsule of claim 4, wherein the Auricularia water extract makes according to following method: standard compliant Auricularia medical material 100g (sugar content is not less than 40g) is cleaned, remove impurity, the extraction pot that places band to stir, add 50 times of water (w/w), extracted filtration 2 hours in 80-90 ℃, filtering residue repeats to extract once, filter, merge secondary filtrate, in 70 ℃ of concentrating under reduced pressure, vacuum is 60-80KPa, and the terminal point concentrated solution is 1.01-1.20g/cm at 70 ℃ of following proportions
3, concentrated solution is cooled to room temperature, weighs, and in stirring the medicinal alcohol that adds 3 times of (w/w) 95% down, the washing secondary filters, and precipitate is at 65 ℃ of following vacuum dryings, and the dry product water content is lower than 5%, extract yield＞15%.
6. the preparation method of an Auricularia water extract is characterized in that getting Auricularia and adds 30-80 times of water (w/w), extracts down at 70-98 ℃, filter, repeat to extract for several times merging filtrate, in 60-80 ℃ of following concentrating under reduced pressure, concentrated solution is cooled to room temperature, stirs to add doubly (w/w) ethanol of 2-5 down, leaves standstill, filter, the precipitate washing with alcohol, vacuum drying obtains the Auricularia water extract.
7. according to the described method of claim, wherein to be controlled at 70 ℃ of following proportions be 1.01-1.20g/cm to the terminal point concentrated solution
3
8. according to the described method of claim 7, wherein standard compliant Auricularia medical material 100g (sugar content is not less than 45g) is cleaned, remove impurity, the extraction pot that places band to stir, add 50 times of water (w/w), extracted filtration 2 hours in 80-90 ℃, filtering residue repeats to extract once, filter, merge secondary filtrate, in 70 ℃ of concentrating under reduced pressure, vacuum is 60-80KPa, and the terminal point concentrated solution is 1.1g/cm at 70 ℃ of following proportions
3, concentrated solution is cooled to room temperature, weighs, and in stirring the medicinal alcohol that adds 3 times of (w/w) 95% down, the washing secondary filters, and precipitate is at 65 ℃ of following vacuum dryings, and the dry product water content is lower than 5%, extract yield＞15%.
9. the Auricularia water extract that makes according to the described method of claim 8.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 00121044 CN1280007A (en) | 2000-07-14 | 2000-07-14 | Jew's-ear blood fat regulating capsule |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 00121044 CN1280007A (en) | 2000-07-14 | 2000-07-14 | Jew's-ear blood fat regulating capsule |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1280007A true CN1280007A (en) | 2001-01-17 |
Family
ID=4588554
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 00121044 Pending CN1280007A (en) | 2000-07-14 | 2000-07-14 | Jew's-ear blood fat regulating capsule |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1280007A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1311761C (en) * | 2003-03-06 | 2007-04-25 | 海南中旭信实业有限公司 | Prepn of health article of edible fungus polysaccharide |
| CN102613540A (en) * | 2012-03-27 | 2012-08-01 | 娄志平 | Dietetic therapy formula for eliminating cardiac rhythm premature beat |
| CN101579118B (en) * | 2009-03-26 | 2013-06-19 | 庆元大山合菌物科技有限公司 | Health food of black fungus soft capsule |
| CN104523770A (en) * | 2014-12-05 | 2015-04-22 | 黑龙江众生生物工程有限公司 | Auriculacin soft capsule and preparation method thereof |
-
2000
- 2000-07-14 CN CN 00121044 patent/CN1280007A/en active Pending
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1311761C (en) * | 2003-03-06 | 2007-04-25 | 海南中旭信实业有限公司 | Prepn of health article of edible fungus polysaccharide |
| CN101579118B (en) * | 2009-03-26 | 2013-06-19 | 庆元大山合菌物科技有限公司 | Health food of black fungus soft capsule |
| CN102613540A (en) * | 2012-03-27 | 2012-08-01 | 娄志平 | Dietetic therapy formula for eliminating cardiac rhythm premature beat |
| CN104523770A (en) * | 2014-12-05 | 2015-04-22 | 黑龙江众生生物工程有限公司 | Auriculacin soft capsule and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108670979A (en) | Adjust-blood lipid norcholesterol prevents the bear gall powder of cardiovascular and cerebrovascular diseases and atherosclerosis | |
| WO2008004804A1 (en) | Trachelospermi caulis extract composition for the treatment and prevention of inflammatory diseases | |
| CN108635375A (en) | Prevent or treats hepatopathy and liver fibrosis and improve the bear gall powder and purposes of liver function | |
| CN108743622A (en) | Immunity of organisms and muscle power are improved using bear gall powder and alleviate the method for organism fatigue | |
| CN110755542A (en) | Formula of uric acid-reducing gout-treating tea and preparation method thereof | |
| CN108324921B (en) | A pharmaceutical composition with cyst removing and gastric mucosa protecting effects, and its preparation method | |
| CN1280007A (en) | Jew's-ear blood fat regulating capsule | |
| CN111870627A (en) | Sobering-up preparation and its preparing method and use | |
| CN108420890B (en) | Composition with blood fat reducing effect and preparation method thereof | |
| CN117481342A (en) | Composition for reducing side effects of drug vomiting as well as preparation method and application thereof | |
| CN116440205A (en) | Tea beverage for preventing and treating non-alcoholic fatty liver and preparation method thereof | |
| JP2004352626A (en) | Anticholesterol agent containing plant-derived component | |
| CN112057535B (en) | Preparation method of traditional Chinese medicine composition for preventing or/and treating dyslipidemia | |
| CN111840448B (en) | Preparation method and application of anti-chapping compound traditional Chinese medicine liposome | |
| RU2071783C1 (en) | Method of agent preparing for diabetes mellitus treatment | |
| CN102526639A (en) | Chinese medicinal composition for treating hyperlipidemia and preparation method thereof | |
| CN113633689A (en) | Oligogalacturonan traditional Chinese medicine composite preparation, preparation method and application | |
| CN102309705A (en) | Medicine for reducing serum uric acid, preparation method thereof and purpose thereof | |
| CN1055232C (en) | Oral preparation capable of enriching yin and moistening intestines | |
| CN1618439A (en) | Broad-specturm medicine for treating snake venom poisoning | |
| CN110680850A (en) | Traditional Chinese medicine health product for reducing blood fat | |
| CN104740345B (en) | Treat Chinese medicine composition of diabetes and preparation method thereof | |
| CN112076249A (en) | Application of perilla leaf extract in preparing medicine for treating inflammatory bowel disease | |
| CN111265627B (en) | Sea cucumber polysaccharide composition for regulating intestinal flora and preparation method and application thereof | |
| CN112089783B (en) | Application of traditional Chinese medicine composition in preparation of medicine for preventing or/and treating obesity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |